CRISPRi-innovaties bieden uitgebreide experimentele opties en flexibiliteit voor onderzoekers die onderzoek naar ziekten en geneesmiddelen vergemakkelijken

WALTHAM, Massachusetts – (BUSINESS WIRE) – Horizon Discovery, een bedrijf van PerkinElmer, Inc. (NYSE: PKI), heeft vandaag aangekondigd dat zijn portfolio voor genbewerking en -modulatie wordt uitgebreid met een nieuwe familie van CRISPR-modulatie (CRISPRmod) -reagentia voor CRISPR interferentie (CRISPRi). CRISPRi stelt wetenschappers in staat om de biologische routes, processen en pathologieën van ziekten beter te begrijpen door genen op transcriptieniveau te onderdrukken, wat uiteindelijk leidt tot nieuwe therapeutische benaderingen.

De nieuwe reagentia omvatten de allereerste commercieel verkrijgbare synthetische single guide RNA’s voor CRISPRi, evenals een patent aangevraagd, dCas9-SALL1-SDS3-repressor die beschikbaar is in mRNA– en lentivirale formaten. Met deze nieuwe technologieën zullen onderzoekers de flexibiliteit hebben om genen in bijna alle cellijnen te onderdrukken, gedurende een bepaalde tijdsduur en op elke schaal, van uitlezingen van afzonderlijke genen tot studies met hoge doorvoer.

Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference

CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research

WALTHAM, Mass.–(BUSINESS WIRE)– Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches.

The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi, as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. With these new technologies, researchers will have the flexibility to repress genes in almost all cell lines, over any length of time, and at any scale from single gene readouts to high-throughput studies.

The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.

Alan Fletcher, SVP Life Sciences at PerkinElmer said, “CRISPRi is gene knockdown, not knockout. It’s CRISPR without the cut, so it offers a temporary and nuanced approach which is ideal for researchers looking to mimic cellular effects of small molecule drugs or do multiplexed gene interrogation. By offering these new reagents, in addition to our existing CRISPR options, we’re primed to aid researchers in achieving even more exciting breakthroughs in the years ahead.”

Horizon Discovery’s Dharmacon technology, with its patented siRNA tools, has been the market leader in gene modulation for more than 20 years. Since the discovery of CRISPR gene editing tools, Horizon has been on the forefront offering guide and nuclease products to enable precision DIY CRISPR knockout and knock-in as well as custom screening and cell line production services. CRISPRmod CRISPRi continues the tradition of innovation by developing novel CRISPR-based transcriptional gene modulation reagents. Portfolio-wide, Horizon helps researchers answer fundamental biological questions leading to therapeutic advancements.

For further information on Horizon Discovery’s CRISPRi technology, please visit: https://horizondiscovery.com/en/applications/crisprmod/crispri.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at https://www.perkinelmer.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005565/en/

Contacts

Media:
Jennifer McNeil

jennifer.mcneil@perkinelmer.com
+1 508.380.2902